|
1
|
Torre LA, Siegel RL and Jemal A: Lung
cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rivera MP: Lung cancer in women:
Differences in epidemiology, biology, histology, and treatment
outcomes. Semin Respir Crit Care Med. 34:792–801. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mohan V, Agarwal R and Singh RP: A novel
alkaloid, evodiamine causes nuclear localization of cytochrome-c
and induces apoptosis independent of p53 in human lung cancer
cells. Biochem Biophys Res Commun. 477:1065–1071. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
D'Amico TA: Angiogenesis in non-small cell
lung cancer. Semin Thorac Cardiovasc Surg. 16:13–18. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Müller-Tidow C, Diederichs S, Thomas M and
Serve H: Genome-wide screening for prognosis-predicting genes in
early-stage non-small-cell lung cancer. Lung Cancer. 45:S145–S150.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rich JN and Bao S: Chemotherapy and cancer
stem cells. Cell Stem Cell. 1:353–355. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dittrich PS and Manz A: Lab-on-a-chip:
Microfluidics in drug discovery. Nat Rev Drug Discov. 5:210–218.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sampsonas F, Ryan D, McPhillips D and
Breen DP: Molecular testing and personalized treatment of lung
cancer. Curr Mol Pharmacol. 7:22–32. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dimou A and Papadimitrakopoulou V:
Non-small cell lung cancer beyond biomarkers: The evolving
landscape of clinical trial design. J Pers Med. 4:386–401. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pass HI, Lavilla C, Canino C, Goparaju C,
Preiss J, Noreen S, Blandino G and Cioce M: Inhibition of the
colony-stimulating-factor-1 receptor affects the resistance of lung
cancer cells to cisplatin. Oncotarget. 7:56408–56421. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gower A, Wang Y and Giaccone G: Oncogenic
drivers, targeted therapies, and acquired resistance in
non-small-cell lung cancer. J Mol Med (Berl). 92:697–707. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kachalaki S, Ebrahimi M, Mohamed
Khosroshahi L, Mohammadinejad S and Baradaran B: Cancer
chemoresistance; biochemical and molecular aspects: a brief
overview. Eur J Pharm Sci. 89:20–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen WX, Liu XM, Lv MM, Chen L, Zhao JH,
Zhong SL, Ji MH, Hu Q, Luo Z, Wu JZ, et al: Exosomes from
drug-resistant breast cancer cells transmit chemoresistance by a
horizontal transfer of microRNAs. PLoS One. 9:e952402014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ardizzoni A, Boni L, Tiseo M, Fossella FV,
Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal
P, Mazzanti P, et al CISCA (Cisplatin vs. Carboplatin)
Meta-analysis Group, : Cisplatin- vs. carboplatin-based
chemotherapy in first-line treatment of advanced non-small-cell
lung cancer: An individual patient data meta-analysis. J Natl
Cancer Inst. 99:847–857. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Torigoe T, Izumi H, Ishiguchi H, Yoshida
Y, Tanabe M, Yoshida T, Igarashi T, Niina I, Wakasugi T, Imaizumi
T, et al: Cisplatin resistance and transcription factors. Curr Med
Chem Anticancer Agents. 5:15–27. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mo EP, Zhang RR, Xu J, Zhang H, Wang XX,
Tan QT, Liu FL, Jiang RW and Cai SH: Calotropin from Asclepias
curasavica induces cell cycle arrest and apoptosis in
cisplatin-resistant lung cancer cells. Biochem Biophys Res Commun.
478:710–715. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Florea AM and Büsselberg D: Cisplatin as
an anti-tumor drug: Cellular mechanisms of activity, drug
resistance and induced side effects. Cancers (Basel). 3:1351–1371.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xie Y, Ma X, Gu L, Li H, Chen L, Li X, Gao
Y, Fan Y, Zhang Y, Yao Y, et al: Prognostic and clinicopathological
significance of survivin expression in renal cell carcinoma: A
systematic review and meta-analysis. Sci Rep. 6:297942016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zeng LF, Zhang RY, Yu ZH, Li S, Wu L,
Gunawan AM, Lane BS, Mali RS, Li X, Chan RJ, et al: Therapeutic
potential of targeting the oncogenic SHP2 phosphatase. J Med Chem.
57:6594–6609. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ren Y, Chen Z, Chen L, Fang B, Win-Piazza
H, Haura E, Koomen JM and Wu J: Critical role of Shp2 in tumor
growth involving regulation of c-Myc. Genes Cancer. 1:994–1007.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chan G, Kalaitzidis D and Neel BG: The
tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis
Rev. 27:179–192. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang X, Dutta U and Shaw LM: SHP2 mediates
the localized activation of Fyn downstream of the α6β4 integrin to
promote carcinoma invasion. Mol Cell Biol. 30:5306–5317. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheng SQ, Fan HY, Xu X, Gao WW, Lv SG, Ye
MH, Wu MJ, Shen XL, Cheng ZJ, Zhu XG and Zhang Y: Over-expression
of LRIG1 suppresses biological function of pituitary adenoma via
attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in
vitro. JJ Huazhong Univ Sci Technolog Med Sci. 36:558–563. 2016.
View Article : Google Scholar
|
|
25
|
Malumbres M and Barbacid M: RAS oncogenes:
The first 30 years. Nat Rev Cancer. 3:459–465. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Giltnane JM and Balko JM: Rationale for
targeting the Ras/MAPK pathway in triple-negative breast cancer.
Discov Med. 17:275–283. 2014.PubMed/NCBI
|
|
27
|
Ksionda O, Melton AA, Bache J, Tenhagen M,
Bakker J, Harvey R, Winter SS, Rubio I and Roose JP: RasGRP1
overexpression in T-ALL increases basal nucleotide exchange on Ras
rendering the Ras/PI3K/Akt pathway responsive to protumorigenic
cytokines. Oncogene. 35:3658–3668. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou XD and Agazie YM: Inhibition of SHP2
leads to mesenchymal to epithelial transition in breast cancer
cells. Cell Death Differ. 15:988–996. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tang C, Luo D, Yang H, Wang Q, Zhang R,
Liu G and Zhou X: Expression of SHP2 and related markers in
non-small cell lung cancer: a tissue microarray study of 80 cases.
Appl Immunohistochem Mol Morphol. 21:386–394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li S, Shi H, Ji F, Wang B, Feng Q, Feng X,
Jia Z, Zhao Q and Qian G: The human lung cancer drug
resistance-related gene BC006151 regulates chemosensitivity in
H446/CDDP cells. Biol Pharm Bull. 33:1285–1290. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tang C, Zhou X, Yang H, Wang Q and Zhang
R: Expression and its clinical significance of SHP2 in non-small
cell lung cancer. Zhongguo Fei Ai Za Zhi. 13:98–101. 2010.(in
Chinese). PubMed/NCBI
|
